Pioglitazone for diabetes prevention

New England Journal of Medicine

Volumn 365, Issue 2, 2011, Pages 183-

  Goldstein, Mark R ^a   Mascitelli, Luca ^b  

^a 9410 Fountain Medical Ct ^*  (United States)

^b Comando Brigata Alpina Julia ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PIOGLITAZONE; VASCULOTROPIN;

BLADDER CANCER; CANCER RISK; DISEASE ASSOCIATION; DRUG EXPOSURE; HEMATURIA; HUMAN; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; TUMOR GROWTH;

DIABETES MELLITUS, TYPE 2; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; THIAZOLIDINEDIONES; URINARY BLADDER NEOPLASMS;

EID: 79960251118     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (4)

1. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROACTIVE Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89. (Pubitemid 41416583)
2. Actos. Lincolnshire, IL: Takeda Pharmaceuticals America, 2004 (package insert).
3. Fauconnet S, Lascombe I, Chabannes E, et al. Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator- activated receptors in bladder cancer cells. J Biol Chem 2002;277:23534-43. (Pubitemid 34952189)
4. FDA drug safety communication: ongoing safety review of Actos (pioglitazone) and potential increased risk of bladder cancer after two years exposure. September 17, 2010. (http://www.fda.gov/Drugs/Drugsafety/ucm226214. htm.)